Pluronic® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin

Vaccine

Volumn 25, Issue 23, 2007, Pages 4602-4610

  Kang, Mi Lan ^a   Jiang, Hu Lin ^a   Kang, Sang Gyun ^a   Guo, Ding Ding ^a   Lee, Deog Yong ^a   Cho, Chong Su ^a   Yoo, Han Sang ^a  

^a Seoul National University   (South Korea)

Author keywords

Bordetella bronchiseptica; Chitosan microsphere; Dermonecrotoxin; Drug delivery system; Intranasal administration; Pluronic F127

Indexed keywords

BACTERIAL ANTIGEN; BORDETELLA BRONCHISEPTICA DERMONECROTOXIN; CHITOSAN; IMMUNOGLOBULIN A ANTIBODY; MICROSPHERE; POLOXAMER; TRIPOLYPHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BACTERIAL TOXIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; BORDETELLA VIRULENCE FACTOR; DERMONECROTIC TOXIN, BORDETELLA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BORDETELLA BRONCHISEPTICA; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENTIATION; DRUG RELEASE; FEMALE; GELATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS MACROPHAGE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SALIVA; ANIMAL; BIOSYNTHESIS; CELL LINE; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRANASAL DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BACTERIAL VACCINES; BORDETELLA BRONCHISEPTICA; CELL LINE; CHITOSAN; FEMALE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED ICR; MICROSPHERES; POLOXAMER; TRANSGLUTAMINASES; TUMOR NECROSIS FACTOR-ALPHA; VIRULENCE FACTORS, BORDETELLA;

EID: 34248324878     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.03.038     Document Type: Article

References (33)

1. Ugwoke M.I., Agu R.U., Verbeke N., and Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 57 (2005) 1640-1665
2. Donovan M.D., Flynn G.L., and Amidon G.L. Absorption of polyethylene glycols 600 through 2000: The molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res 7 (1990) 863-868
3. Sarker M.A. Drug metabolism in the nasal mucosa. Pharm Res 9 (1992) 1-9
4. Türker S., Onur E., and Ózer Y. Nasal route and drug delivery systems. Pharm World Sci 26 (2004) 137-142
5. Chandy T., and Sharma Cp. Chitosan-as a biomaterial. Biometer Artif Cells Artif Organs 18 (1990) 1-24
6. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., and Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51 (2001) 81-96
7. Brooking J., Davis S.S., and Illum L. Transport of nanoparticles across the rat nasal mucosa. J Drug Target 9 (2001) 267-279
8. Soane R.J., Frier M., Perkins A.C., Jones N.S., Davis S.S., and Illum L. Evaluation of the clearance characteristics of bioadhesive system in humans. Int J Pharm 178 (1999) 55-65
9. Pereswetoff-Morath L. Microspheres as nasal drug delivery system. Adv Drug Deliv Rev 29 (1998) 185-194
10. Chowdary K.P., and Rao Y.S. Mucoadhesive microspheres for controlled drug delivery. Biol Pharm Bull 27 (2004) 1717-1724
11. Sinha V.R., Singla A.K., Wadhawan S., Kaushik R., Kumria R., Bansal K., et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 274 (2004) 1-33
12. Varshosaz J., Sadrai H., and Alinagari R. Nasal delivery of insulin using chitosan microspheres. J Microencapsul 21 (2004) 761-774
13. Sankar C., Rani M., Srivastava A.K., and Mishra B. Chitosan based pentazocine microspheres for intranasal systemic delivery: development and biopharmaceutical evaluation. Pharmazie 56 (2001) 223-226
14. Jiang H.L., Park I.K., Shin N.R., Kang S.G., Yoo H.S., Kim S.I., et al. In vitro study of the immune stimulating activity of an atrophic rhinitis vaccine associated to chitosan microspheres. Eur J Pharm Biopharm 58 (2004) 471-476
15. Kang M.L., Kang S.G., Jiang H.L., Shin S.W., Lee D.Y., Ahn J.M., et al. In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT. Eur J Pharm Biopharm 63 (2006) 215-220
16. Bharadwaj R., and Blanchard J. Controlled-release delivery system for the alpha-MSH analog Melanotan-I using poloxamer 407. J Pharm Sci 85 (1996) 915-919
17. Wang P.L., and Johnston T.P. Enhanced stability of two model proteins in an agitated solution environment using poloxamer 407. J Parenter Sci Technol 47 (1993) 183-189
18. Katakam M., Bell L.N., and Banga A.K. Effect of surfactants on the physical stability of rhGH. J Pharm Sci 84 (1995) 713-716
19. Jain N., Aswal P., Goyal P., and Bahadur P. Micellar structure of an ethylene oxide-propylene oxide block co-polymer. A small angle neutron scattering study. J Phys Chem 102 (1998) 8452-8460
20. Gilbert J.C., Hadgraft J., Bye A., and Brookes L. Drug release from pluronic F127 gels. Int J Pharm 32 (1986) 223-228
21. Paavola A., Kilpelainen I., Yliruusi J., and Rosenberg P. Controlled release injectable liposomal gel of ibuprofen for epidural analgesia. Int J Pharm 199 (2000) 85-93
22. Wenzel J.G.W., Balajii K.S.S., Koushik C., Navarre S.H., Duran C.H., and Kompella U. Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J Control Rel 85 (2002) 51-59
23. Rutter J.M., Francis L.M.A., and Sansom B.F. Virulence of Bordetella bronchiseptica from pigs with or without atrophic rhinitis. J Med Microbiol 15 (1982) 105-116
24. Brockmeier S.L., Register K.B., Magyar T., Lax A.J., Pullinger G.D., and Kunkle R.A. Role of the dermonecrotic toxin of Bordetella bronchiseptica in the pathogenesis of respiratory disease in swine. Infect Immun 70 (2002) 481-490
25. Shin N.R., Kim J.M., and Yoo H.S. Control of swine respiratory disease using egg yolk antibodies. 1. Analysis of immunogens of Bordetella bronchiseptica, Pasteurella multocida and Actinobacillus pleuropneumoniae and production of IgY. Korean J Vet Res 40 (2000) 551-561
26. Xu Y.M., and Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 250 (2003) 215-226
27. Shiraishi S., Imai T., and Otagiri M. Controlled release of indomethacin by chitosan-polyelectrolyte complex: optimization and in vivo/in vitro evaluation. J Control Rel 25 (1993) 217-225
28. Calvo P., Remuñan-López C., Vila-Jato J.L., and Alonso M.J. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 14 (1997) 1431-1436
29. Miglani (Dhawan) S. Preparation and evaluation of controlled release oral dosage forms of glipizide and nifedipine [dissertation]. PhD thesis, University Institute of Pharmaceutical Sciences, Punjab University, Chandigarh, India, 2002.
30. Eldridge J.H., Hammond C.J., Meulbroeck J.A., Staas J.K., Gilley R.M., and Tice T.R. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the payer's patches. J Control Rel 11 (1990) 205-214
31. ®/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine 20 (2002) 771-823
32. ® F127-based systemic vaccine delivery system. Vaccine 22 (2004) 2396-2405
33. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., and Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10 (1992) 75-88